SlideShare a Scribd company logo
1 of 25
Download to read offline
Drug Therapy for
Hypercholesteromia &
Dyslipidemia
URVI KOLHATKAR
What is Hyperlipidemia?
• Characterized by abnormally high concentration
of Fats and lipids in the blood.
• Increased level of Low Density Lipoproteins as
well as Triacylglycerols and decreased levels of
High Density Lipoproteins.
• Hyperlipidemia is a major cause of
Atherosclerosis and Atherosclerosis induced
conditions such as Coronary Heart Disease(CHD)
, Unstable Angina (Unexpected Chest pain),
Myocardial Infarction (Heart attack).
Causes of Hyperlipidemia
• Diet or change in Lifestyle.
• Obesity
• Pregnancy
• Acute Hepatitis
• Diabetes Mellitus
• Nephrotic Syndrome
• Obstructive Liver Disease
• Single Inherited Gene defect in Lipoproteins metabolism.
ATHEROGENIC AND ANTIATHEROGENIC LIPOPROTEINS
THE ATHEROGENIC LIPOPROTEIN
PHENOTYPE:
1.Low Density Lipoprotein- Derived
from VLDL in the capillary beds.
Measured by friedewald formula.
2.Plasma Lipoprotein A : Complex of
LDL and large glycoprotein apoA.
Interaction with proteoglycans-oxidative
modification-Key event for CHD.
3.Very Low Density Lipoprotein: High
VLDL conc indicates, high triglyceride
concentration.
ANTIATHEROGENIC
High Density Lipoprotein: Protective
factor against coronary heart disease.
Reverse cholesterol transport.
Lack apoB
LIPID METABOLISM
DRUG THERAPY OF DYSLIPIDEMIA
1.STATINS :
Competitive Inhibitors of (3-Hydroxy-3-
methylglutaryl) HMG-CoA reductase, which lowers
LDL by inhibiting an early rate-limiting step in
cholesterol synthesis.
• Drugs under this class are:
Lovastatin,pravastatin,simvastatin,Atorvastatin,fluvasta
tin,rosuvastatin and pitavastatin.
Mechanism of Action:
By reducing the conversion of HMG CoA reductase to Mevalonate, Statins inhibit an
early rate-limiting step in cholesterol biosynthesis.
By reducing the hepatic cholesterol synthesis, they also lead to an increased
expression of LDL receptor gene.
Statin therapy leads to enhanced production of vasodilator Nitric oxide,
contributing to an improved endothelial function.
• Statins lead to plaque stabilization and modulate cellularity of the artery wall.
• Statins decreased the levels of CRP, thus they lower the risk of CHD and inhibit
the inflammatory processes.
• Statins prevent susceptibility of Lipoprotein to oxidation.
• Statins repurposed for increasing the bone cell volume and to bolster the bones,
this could be a new therapeutic breakthrough for treatment of Osteoporosis.
Ref:http://www.ncbi.nlm.nih.gov/pubmed/10583956
Therapeutic Uses:
• Effective in all types of hyperlipidemias
• Patients with homozygous familial hypercholesteromia benefit less
with this drug class.
Adverse Effects:
a.Liver:
• Hepatotoxicity.
• Hepatic Insufficiency can cause drug
accumulation.
b.Muscle:
• Muscle myopathy and rhabdomyolysis has
also been reported rarely.
Drug Interactions:
• The HMG CoA reductase inhibitors could
increase warfarin levels.
Contraindications:
Statins are contraindicated during pregnancy
and for nursing mothers.
Why are statins administered before
bedtime or evening?
Hepatic cholesterol synthesis is maximal between
midnight and 2:00 AM, thus statins with a t1/2 of
4 hours should be administered in the evening
with a recommended dose of 20 mg.
2.The Fibrates:
• This drug class includes Fenofibrate and gemfibrozil.
• These drugs are derivative of fibric acid and they execute the lipid
lowering action by decreasing the serum triacylglycerols and by
increasing the serum HDL levels.
Mechanism of Action: Lipid lowering action by interaction with
peroxisome proliferator-activated receptors (PPARs). This receptor
supergene family regulates the Lipid Metabolism.
Fibrate mediated PPAR gene expression leads to decreased triglycerol
concentration by increasing the expression of lipoprotein lipase and
decreasing apolipoprotein C II concentration.
THERAPEUTIC USES:
Gemfibrozil and fenofibrate are particulary useful in treating Type III
Hyperlipidemia. (high IDL)
Adverse Effects:
• Gastrointestinal Disturbances
• Increased lithogenecity of bile
• Myopathy syndrome
• Myositis
Contraindications: Their safety has not been established for
pregnant or lactating women. Patients with renal or hepatic
insufficiency or pre-existing gall bladder disease should not be
administered with this class of hyperlipidemic drugs.
Drug Interactions: Compete with coumarin anti-coagulants for
binding sites on plasma proteins, hence INR should be
monitored.
3.Niacin (Nicotinic acid)
MECHANISM OF ACTION:
They exert their effect on lipolysis by
inhibiting adipocyte adenyl cyclase.
GPCR109A has been identified and
established for niacin, its mRNA is highly
expressed in adipose tissue and spleen,
high affinity nicotinic acid binding sites.
Pharmacokinetics :
• Niacin is biotransformed to nicotinamide, which is incorporated
in its cofactor NAD+. These metabolites excreted in the urine.
Adverse Effects: Cutaneous Flush, Pruritus,
hyperuricemia, and Gout. Impaired Glucose tolerance and
hepatotoxicity are also rarely observed.
4.Bile acid-Sequestrants
Mechanism of Action : Colestipol and cholestyramine are
anion exchange resins.
Lowered Bile acid concentration= Hepatocyte conversion of
cholesterol to bile acid increased.
5.EZETIMIBE (Cholesterol Absorption Inhibitor)
• Selectively inhibits absorption of Dietary and
biliary cholesterol in the small intestine.
• Blockade of sterol transporter on the brush border
membrane of Intestinal epithelial cells.
• Thus decreases delivery of cholesterol to the liver
& increases expression of LDL receptors.
• Cholesterol content of atherogenic particles also
decreases.
• Niemann-Pick C1 Like 1 Protein transporter has been
discovered that appears to be critical for intestinal
cholesterol absorption.
Summary :
TYPE OF DRUG MECHANISM OF ACTION
STATINS Inhibits a rate limiting step in Cholesterol
Biosynthesis
FIBRATES Modulates Lipid metabolism through
PPAR supergene family
NIACIN Inhibits Lipolysis in adipose tissue
BILE ACID SEQUESTRANTS Anion exchange resins that lower bile
acid concentration
EZETIMIBE Inhibits absorption of cholesterol from
the small intestine
Study Questions:
1. Which of the following drug decreases de-novo cholesterol synthesis
by inhibiting the enzyme 3-hydroxy-3-methylglutaryl coenzyme A
reductase?
a)Fenofibrate
b)Niacin
c)Lovastatin
d)Gemfibrozil
2.Which one of the following drug causes decrease in liver triacylglycerol
synthesis by limiting available free fatty acids needed as building blocks for this
pathway?
a)Niacin
b)Fenofibrate
c)Cholestyramine
d)Gemfibrozil
3.Which of the following drugs binds bile acids in the intestine, thus preventing
their return to the liver via the enterohepatic circulation?
a)Niacin
b)Fluvastatin
c)Cholestyramine
d)Lovastatin
REFERENCES:
• The NEW ENGLAND JOURNAL OF MEDICINE:
http://www.nejm.org/doi/full/10.1056/nejm199506013322207
• http://science.sciencemag.org/content/193/4258/1094.short
• NCBI : Ref:http://www.ncbi.nlm.nih.gov/pubmed/10583956
• Lippincott’s illustrated Reviews
• Prevalence and treatment of hyperlipidemia in patients with chronic hepatitis C infection:
http://www.ncbi.nlm.nih.gov/pubmed/19398918
• Goodman & Gilman’s The Pharmacological Basics of Therapeutics
Thank You.

More Related Content

What's hot (20)

General prescribing guidelines_for_pregnancy_and_breast_feeding
General prescribing guidelines_for_pregnancy_and_breast_feedingGeneral prescribing guidelines_for_pregnancy_and_breast_feeding
General prescribing guidelines_for_pregnancy_and_breast_feeding
 
Antihyperlipidemic drugs
Antihyperlipidemic drugsAntihyperlipidemic drugs
Antihyperlipidemic drugs
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
Antianginal drugs
Antianginal drugsAntianginal drugs
Antianginal drugs
 
Hyperlipidemia, pharmacology
Hyperlipidemia, pharmacologyHyperlipidemia, pharmacology
Hyperlipidemia, pharmacology
 
PHARMACOTHERAPY OF MYOCARDIAL INFARCTION
PHARMACOTHERAPY OF MYOCARDIAL INFARCTIONPHARMACOTHERAPY OF MYOCARDIAL INFARCTION
PHARMACOTHERAPY OF MYOCARDIAL INFARCTION
 
Drugs used in Hyperlipidemia
Drugs used in HyperlipidemiaDrugs used in Hyperlipidemia
Drugs used in Hyperlipidemia
 
Hyperlipidemia.pptx
Hyperlipidemia.pptxHyperlipidemia.pptx
Hyperlipidemia.pptx
 
Angina ant its pharmacotherapy
Angina ant its pharmacotherapyAngina ant its pharmacotherapy
Angina ant its pharmacotherapy
 
Abnormalities in lipoproteinemia
Abnormalities in  lipoproteinemiaAbnormalities in  lipoproteinemia
Abnormalities in lipoproteinemia
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
Diabetes pharmacotherapy(1)
Diabetes pharmacotherapy(1)Diabetes pharmacotherapy(1)
Diabetes pharmacotherapy(1)
 
Management of Hyperlipidemia
Management of HyperlipidemiaManagement of Hyperlipidemia
Management of Hyperlipidemia
 
ACE Inhibitors
ACE InhibitorsACE Inhibitors
ACE Inhibitors
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
Antihyperlipidemic drug
Antihyperlipidemic drugAntihyperlipidemic drug
Antihyperlipidemic drug
 
Hypoglycemic agents
Hypoglycemic agentsHypoglycemic agents
Hypoglycemic agents
 
Antiarrhythmic agent
Antiarrhythmic agentAntiarrhythmic agent
Antiarrhythmic agent
 
Pharmaceutical legislation in India
Pharmaceutical legislation in IndiaPharmaceutical legislation in India
Pharmaceutical legislation in India
 
Drug Induced Pulmonary Diseases
Drug Induced Pulmonary DiseasesDrug Induced Pulmonary Diseases
Drug Induced Pulmonary Diseases
 

Similar to Hyperlipidemia pharmacotherapy

Management of atherosclerosis and hyperlipidemia.pdf
Management of atherosclerosis and hyperlipidemia.pdfManagement of atherosclerosis and hyperlipidemia.pdf
Management of atherosclerosis and hyperlipidemia.pdfHemanhuelCTankxes
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugsajaykumarbp
 
Lipid metabolism and hypolipedemic drugs
Lipid metabolism and hypolipedemic drugsLipid metabolism and hypolipedemic drugs
Lipid metabolism and hypolipedemic drugsUrmila Aswar
 
Hypolipidemic Drugs, by Baqir Naqvi.pptx
Hypolipidemic Drugs, by Baqir Naqvi.pptxHypolipidemic Drugs, by Baqir Naqvi.pptx
Hypolipidemic Drugs, by Baqir Naqvi.pptxDr. Baqir Raza Naqvi
 
DRUGS OF HYPERLIPIDEMIA.pptx
DRUGS OF HYPERLIPIDEMIA.pptxDRUGS OF HYPERLIPIDEMIA.pptx
DRUGS OF HYPERLIPIDEMIA.pptxMKashif39
 
DRUGS OF HYPERLIPIDEMIA 123.pptx
DRUGS OF HYPERLIPIDEMIA 123.pptxDRUGS OF HYPERLIPIDEMIA 123.pptx
DRUGS OF HYPERLIPIDEMIA 123.pptxKaleemRajpoot4
 
HS-Hypolipidemic_Drugs.pdf
HS-Hypolipidemic_Drugs.pdfHS-Hypolipidemic_Drugs.pdf
HS-Hypolipidemic_Drugs.pdfSanjayaManiDixit
 
Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia Dr Htet
 
Drugs for Hyperlipoproteinemia.ppt
Drugs for Hyperlipoproteinemia.pptDrugs for Hyperlipoproteinemia.ppt
Drugs for Hyperlipoproteinemia.pptAhmad Kharousheh
 
Hypolipideamic drugs.pptx
Hypolipideamic drugs.pptxHypolipideamic drugs.pptx
Hypolipideamic drugs.pptxManish Gautam
 
METABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptxMETABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptxMukundGurav
 
Hypolipidaemic vinay
Hypolipidaemic vinayHypolipidaemic vinay
Hypolipidaemic vinayvinay tuteja
 
Hyperlipidemia (Hyperlipoproteinaemia).pptx
Hyperlipidemia (Hyperlipoproteinaemia).pptxHyperlipidemia (Hyperlipoproteinaemia).pptx
Hyperlipidemia (Hyperlipoproteinaemia).pptxezaldeen2013
 

Similar to Hyperlipidemia pharmacotherapy (20)

Management of atherosclerosis and hyperlipidemia.pdf
Management of atherosclerosis and hyperlipidemia.pdfManagement of atherosclerosis and hyperlipidemia.pdf
Management of atherosclerosis and hyperlipidemia.pdf
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugs
 
Lipid metabolism and hypolipedemic drugs
Lipid metabolism and hypolipedemic drugsLipid metabolism and hypolipedemic drugs
Lipid metabolism and hypolipedemic drugs
 
Hypolipidemic Drugs, by Baqir Naqvi.pptx
Hypolipidemic Drugs, by Baqir Naqvi.pptxHypolipidemic Drugs, by Baqir Naqvi.pptx
Hypolipidemic Drugs, by Baqir Naqvi.pptx
 
DRUGS OF HYPERLIPIDEMIA.pptx
DRUGS OF HYPERLIPIDEMIA.pptxDRUGS OF HYPERLIPIDEMIA.pptx
DRUGS OF HYPERLIPIDEMIA.pptx
 
DRUGS OF HYPERLIPIDEMIA 123.pptx
DRUGS OF HYPERLIPIDEMIA 123.pptxDRUGS OF HYPERLIPIDEMIA 123.pptx
DRUGS OF HYPERLIPIDEMIA 123.pptx
 
HS-Hypolipidemic_Drugs.pdf
HS-Hypolipidemic_Drugs.pdfHS-Hypolipidemic_Drugs.pdf
HS-Hypolipidemic_Drugs.pdf
 
Hypolipidaemic drugs
Hypolipidaemic drugsHypolipidaemic drugs
Hypolipidaemic drugs
 
Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia
 
hyperlipidemic drugs..pptx
hyperlipidemic drugs..pptxhyperlipidemic drugs..pptx
hyperlipidemic drugs..pptx
 
Drugs for Hyperlipoproteinemia.ppt
Drugs for Hyperlipoproteinemia.pptDrugs for Hyperlipoproteinemia.ppt
Drugs for Hyperlipoproteinemia.ppt
 
Lipid disorders
Lipid disorders Lipid disorders
Lipid disorders
 
Hypolipideamic drugs.pptx
Hypolipideamic drugs.pptxHypolipideamic drugs.pptx
Hypolipideamic drugs.pptx
 
METABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptxMETABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptx
 
Antihyperlipidemia
AntihyperlipidemiaAntihyperlipidemia
Antihyperlipidemia
 
Antihyperlipidemic.pdf
Antihyperlipidemic.pdfAntihyperlipidemic.pdf
Antihyperlipidemic.pdf
 
HYPOLIPIDEMIC DRUGS
HYPOLIPIDEMIC DRUGSHYPOLIPIDEMIC DRUGS
HYPOLIPIDEMIC DRUGS
 
Hypolipidaemic vinay
Hypolipidaemic vinayHypolipidaemic vinay
Hypolipidaemic vinay
 
Hyperlipidemia (Hyperlipoproteinaemia).pptx
Hyperlipidemia (Hyperlipoproteinaemia).pptxHyperlipidemia (Hyperlipoproteinaemia).pptx
Hyperlipidemia (Hyperlipoproteinaemia).pptx
 

Recently uploaded

Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 

Recently uploaded (20)

How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 

Hyperlipidemia pharmacotherapy

  • 1. Drug Therapy for Hypercholesteromia & Dyslipidemia URVI KOLHATKAR
  • 2. What is Hyperlipidemia? • Characterized by abnormally high concentration of Fats and lipids in the blood. • Increased level of Low Density Lipoproteins as well as Triacylglycerols and decreased levels of High Density Lipoproteins. • Hyperlipidemia is a major cause of Atherosclerosis and Atherosclerosis induced conditions such as Coronary Heart Disease(CHD) , Unstable Angina (Unexpected Chest pain), Myocardial Infarction (Heart attack).
  • 3. Causes of Hyperlipidemia • Diet or change in Lifestyle. • Obesity • Pregnancy • Acute Hepatitis • Diabetes Mellitus • Nephrotic Syndrome • Obstructive Liver Disease • Single Inherited Gene defect in Lipoproteins metabolism.
  • 4. ATHEROGENIC AND ANTIATHEROGENIC LIPOPROTEINS THE ATHEROGENIC LIPOPROTEIN PHENOTYPE: 1.Low Density Lipoprotein- Derived from VLDL in the capillary beds. Measured by friedewald formula. 2.Plasma Lipoprotein A : Complex of LDL and large glycoprotein apoA. Interaction with proteoglycans-oxidative modification-Key event for CHD. 3.Very Low Density Lipoprotein: High VLDL conc indicates, high triglyceride concentration. ANTIATHEROGENIC High Density Lipoprotein: Protective factor against coronary heart disease. Reverse cholesterol transport. Lack apoB
  • 6. DRUG THERAPY OF DYSLIPIDEMIA 1.STATINS : Competitive Inhibitors of (3-Hydroxy-3- methylglutaryl) HMG-CoA reductase, which lowers LDL by inhibiting an early rate-limiting step in cholesterol synthesis. • Drugs under this class are: Lovastatin,pravastatin,simvastatin,Atorvastatin,fluvasta tin,rosuvastatin and pitavastatin.
  • 8. By reducing the conversion of HMG CoA reductase to Mevalonate, Statins inhibit an early rate-limiting step in cholesterol biosynthesis. By reducing the hepatic cholesterol synthesis, they also lead to an increased expression of LDL receptor gene. Statin therapy leads to enhanced production of vasodilator Nitric oxide, contributing to an improved endothelial function. • Statins lead to plaque stabilization and modulate cellularity of the artery wall. • Statins decreased the levels of CRP, thus they lower the risk of CHD and inhibit the inflammatory processes. • Statins prevent susceptibility of Lipoprotein to oxidation. • Statins repurposed for increasing the bone cell volume and to bolster the bones, this could be a new therapeutic breakthrough for treatment of Osteoporosis. Ref:http://www.ncbi.nlm.nih.gov/pubmed/10583956
  • 9. Therapeutic Uses: • Effective in all types of hyperlipidemias • Patients with homozygous familial hypercholesteromia benefit less with this drug class.
  • 10. Adverse Effects: a.Liver: • Hepatotoxicity. • Hepatic Insufficiency can cause drug accumulation. b.Muscle: • Muscle myopathy and rhabdomyolysis has also been reported rarely.
  • 11. Drug Interactions: • The HMG CoA reductase inhibitors could increase warfarin levels. Contraindications: Statins are contraindicated during pregnancy and for nursing mothers.
  • 12. Why are statins administered before bedtime or evening?
  • 13. Hepatic cholesterol synthesis is maximal between midnight and 2:00 AM, thus statins with a t1/2 of 4 hours should be administered in the evening with a recommended dose of 20 mg.
  • 14. 2.The Fibrates: • This drug class includes Fenofibrate and gemfibrozil. • These drugs are derivative of fibric acid and they execute the lipid lowering action by decreasing the serum triacylglycerols and by increasing the serum HDL levels. Mechanism of Action: Lipid lowering action by interaction with peroxisome proliferator-activated receptors (PPARs). This receptor supergene family regulates the Lipid Metabolism. Fibrate mediated PPAR gene expression leads to decreased triglycerol concentration by increasing the expression of lipoprotein lipase and decreasing apolipoprotein C II concentration.
  • 15. THERAPEUTIC USES: Gemfibrozil and fenofibrate are particulary useful in treating Type III Hyperlipidemia. (high IDL)
  • 16. Adverse Effects: • Gastrointestinal Disturbances • Increased lithogenecity of bile • Myopathy syndrome • Myositis Contraindications: Their safety has not been established for pregnant or lactating women. Patients with renal or hepatic insufficiency or pre-existing gall bladder disease should not be administered with this class of hyperlipidemic drugs. Drug Interactions: Compete with coumarin anti-coagulants for binding sites on plasma proteins, hence INR should be monitored.
  • 17. 3.Niacin (Nicotinic acid) MECHANISM OF ACTION: They exert their effect on lipolysis by inhibiting adipocyte adenyl cyclase. GPCR109A has been identified and established for niacin, its mRNA is highly expressed in adipose tissue and spleen, high affinity nicotinic acid binding sites.
  • 18. Pharmacokinetics : • Niacin is biotransformed to nicotinamide, which is incorporated in its cofactor NAD+. These metabolites excreted in the urine. Adverse Effects: Cutaneous Flush, Pruritus, hyperuricemia, and Gout. Impaired Glucose tolerance and hepatotoxicity are also rarely observed.
  • 19. 4.Bile acid-Sequestrants Mechanism of Action : Colestipol and cholestyramine are anion exchange resins. Lowered Bile acid concentration= Hepatocyte conversion of cholesterol to bile acid increased.
  • 20. 5.EZETIMIBE (Cholesterol Absorption Inhibitor) • Selectively inhibits absorption of Dietary and biliary cholesterol in the small intestine. • Blockade of sterol transporter on the brush border membrane of Intestinal epithelial cells. • Thus decreases delivery of cholesterol to the liver & increases expression of LDL receptors. • Cholesterol content of atherogenic particles also decreases. • Niemann-Pick C1 Like 1 Protein transporter has been discovered that appears to be critical for intestinal cholesterol absorption.
  • 21. Summary : TYPE OF DRUG MECHANISM OF ACTION STATINS Inhibits a rate limiting step in Cholesterol Biosynthesis FIBRATES Modulates Lipid metabolism through PPAR supergene family NIACIN Inhibits Lipolysis in adipose tissue BILE ACID SEQUESTRANTS Anion exchange resins that lower bile acid concentration EZETIMIBE Inhibits absorption of cholesterol from the small intestine
  • 22. Study Questions: 1. Which of the following drug decreases de-novo cholesterol synthesis by inhibiting the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase? a)Fenofibrate b)Niacin c)Lovastatin d)Gemfibrozil
  • 23. 2.Which one of the following drug causes decrease in liver triacylglycerol synthesis by limiting available free fatty acids needed as building blocks for this pathway? a)Niacin b)Fenofibrate c)Cholestyramine d)Gemfibrozil 3.Which of the following drugs binds bile acids in the intestine, thus preventing their return to the liver via the enterohepatic circulation? a)Niacin b)Fluvastatin c)Cholestyramine d)Lovastatin
  • 24. REFERENCES: • The NEW ENGLAND JOURNAL OF MEDICINE: http://www.nejm.org/doi/full/10.1056/nejm199506013322207 • http://science.sciencemag.org/content/193/4258/1094.short • NCBI : Ref:http://www.ncbi.nlm.nih.gov/pubmed/10583956 • Lippincott’s illustrated Reviews • Prevalence and treatment of hyperlipidemia in patients with chronic hepatitis C infection: http://www.ncbi.nlm.nih.gov/pubmed/19398918 • Goodman & Gilman’s The Pharmacological Basics of Therapeutics